Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...
Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback